micro-community-banner
 
  • Saved

1yr

Did you know? Originally developed in Switzerland, the HypoCat™ vaccine helps to reduce cat allergies by neutralizing Fel D 1, the protein most responsible for causing allergic reactions to cat dander in humans. When given to cats, the vaccine triggers their immune system to create antibodies against Fel D 1. Results from four separate studies have reported that the HypoCat™ vaccine caused no negative side effects for cats. The vaccine is projected to be available in the U.S. by the end of 2024. A similar vaccine for dogs is currently in the early stages of development.

How could vaccines like HypoCat™ revolutionize allergy treatments and improve the lives of pet owners with allergies?

background

How could vaccines like HypoCat™ revolutionize allergy treatments and improve the lives of pet owners with allergies?

  • Saved

1yr
Background Image DesktopBackground Image Mobile

Self-control isn't always effortful. Research shows successful self-control links to quick conflict resolution, automated habits, and strategic anticipation. By building better habits and planning for challenges, self-control becomes less about resisting impulses and more about effortless, effective strategies.

Read More

  • Saved

1yr
Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment-A Literature Review - PubMed

Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment-A Literature Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38541824/

Thrombotic microangiopathy (TMA) has been observed in some patients receiving interferon beta (IFNβ) therapy for relapsing-remitting multiple sclerosis, but little is known about its clinical features and outcomes. We searched...

Thrombotic microangiopathy (TMA) in IFNβ-treated multiple sclerosis patients often presents with acute kidney injury, prodromal symptoms, and is treated with plasma exchange or eculizumab, improving renal outcomes in severe cases.

  • Saved

1yr
Comments on energy conservation treatments for MS-related fatigue and a new proposal - PubMed

Comments on energy conservation treatments for MS-related fatigue and a new proposal - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38735103/

Psychological treatments of MS-related fatigue mostly depend on energy conservation programs. We argue that the evidence for energy conservation training is weak - in contrast to some reviews on this...

The authors critique energy conservation programs for MS-related fatigue and propose a three-step treatment approach, focusing on fatigue as a subjective feeling, using Progressive Muscle Relaxation to interrupt fatigue and improve treatment outcomes.

  • Saved

1yr
Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review - PubMed

Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39263485/

The pathogenesis of steroid-refractory IRM and the treatment regimen remain unclear. A large number of studies need to be conducted to validate or update our proposed treatment approach.

Steroid-refractory immune checkpoint inhibitor-related myocarditis (IRM) management may involve abatacept, alemtuzumab, tocilizumab, or combination therapies tailored to specific comorbidities, with further research needed to refine treatment strategies.